Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CJM112 versus placebo for moderate to severe inflammatory acne
NL-OMON47130Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acne vulgaris comparing CJM112 with Placebo (2 arms). Primary endpoint: Efficacy on facial inflammatory lesion counts. Started Dec 2016; status: active, not recruiting.
02
Drugs
CJM112
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NL-OMON47130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47130.